<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03503162</url>
  </required_header>
  <id_info>
    <org_study_id>CL00044</org_study_id>
    <nct_id>NCT03503162</nct_id>
  </id_info>
  <brief_title>Evaluation of the Bowel Cleansing in Hospitalized Patients Using Pure-Vu System</brief_title>
  <official_title>Evaluation of the Bowel Cleansing in Hospitalized Patients Using Pure-Vu System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Motus GI Medical Technologies Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Motus GI Medical Technologies Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the potential improvement in colonoscopy procedure's&#xD;
      outcomes when using the Pure-Vu System in hospitalized patients who are indicated for&#xD;
      colonoscopy procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center, prospective, single arm study will include up to 100 patients (20-40&#xD;
      patients per site), aimed at evaluating the performance of the Pure-Vu System in cleansing&#xD;
      hospitalized patients' colon who are indicated for standard colonoscopy procedure.&#xD;
&#xD;
      Subjects will be enrolled at up to 4 clinical sites in the United States and Europe. Subjects&#xD;
      who meet the eligibility criteria will be prescribed a standard bowel preparation bowel&#xD;
      preparation regimen including diet restrictions and oral bowel preparation.&#xD;
&#xD;
      Following the bowel preparation, the patient will undergo colonoscopy with the Pure-Vu&#xD;
      system.&#xD;
&#xD;
      In case of inadequate bowel preparation, as per the nurse report and / or BBPS &lt; 2, in at&#xD;
      least one of the colon segments, prior Pure-Vu use, the physician will complete a&#xD;
      questionnaire on the patient's management standard of care assuming the absence of Pure-Vu.&#xD;
&#xD;
      Follow-up will be conducted at 48 hours (± 48 hours) post procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2018</start_date>
  <completion_date type="Actual">May 20, 2019</completion_date>
  <primary_completion_date type="Actual">May 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Rate of Adequate Cleansing Level Before and After the Use of the Pure-Vu System</measure>
    <time_frame>up to 2 hours</time_frame>
    <description>The rate of adequate cleansing level in each colon segment before and after use of Pure-Vu will be evaluated using the Boston Bowel Preparation Scale (BBPS). Segment score of 0-3 given to each of the 3 segments of the colon (Left side, Transverse and right side) summed for the maximum score of 9 (0= dirtiest and 9= pristine).&#xD;
An adequate cleansing procedure will be considered when all the colon segments will be graded as 2 or above.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Gastrointestinal Disease</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Colonoscopy with Pure-Vu System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard colonoscopy procedure with Pure-Vu System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pure-Vu System</intervention_name>
    <description>The Pure-Vu System is FDA cleared device and CE marking received in February 2018, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.</description>
    <arm_group_label>Colonoscopy with Pure-Vu System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hospitalized patients who are indicated for a screening, diagnostic, surveillance or&#xD;
             therapeutic colonoscopy&#xD;
&#xD;
          2. Patients' age &gt; 22 years&#xD;
&#xD;
          3. Patient has signed the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with known Inflammatory Bowel Disease and / or active Colitis&#xD;
&#xD;
          2. Patients with active diverticulitis&#xD;
&#xD;
          3. Patients with known or detected (during colonoscopy) bowel obstruction&#xD;
&#xD;
          4. Patients with BMI ≤ 18&#xD;
&#xD;
          5. Patients with ascites Child Pugh C&#xD;
&#xD;
          6. Patients who are 30 days post-transplant&#xD;
&#xD;
          7. Patients treated with Peritoneal dialysis&#xD;
&#xD;
          8. Patients under active IV inotropic medications&#xD;
&#xD;
          9. Patients with LVAD&#xD;
&#xD;
         10. Patients who have active anticoagulant medications (excluding aspirin) or dual&#xD;
             antiplatelet therapy in their system prior to the procedure. (Note: to avoid exclusion&#xD;
             therapy should be discontinued 48 hours or greater prior to the procedure based on&#xD;
             discretion of physician)&#xD;
&#xD;
         11. Subjects with known coagulation disorder (INR ≥ 2 or platelets &lt;50,000)&#xD;
&#xD;
         12. Subjects with hemodynamic instability.&#xD;
&#xD;
         13. Pregnancy (as stated by patient) or breast feeding&#xD;
&#xD;
         14. Subjects with altered mental status/inability to provide informed consent&#xD;
&#xD;
         15. Patients who have participated in another interventional clinical study in the last 2&#xD;
             months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annie Choi</last_name>
    <role>Study Director</role>
    <affiliation>Motus GI Technologies Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 9, 2018</study_first_submitted>
  <study_first_submitted_qc>April 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <results_first_submitted>September 14, 2020</results_first_submitted>
  <results_first_submitted_qc>March 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2021</results_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bowel prepartion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>no plan to share the individual participated date with other researchers at this point.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03503162/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Colonoscopy With Pure-Vu System</title>
          <description>Inpatient colonoscopies with Pure-Vu System- Single Arm&#xD;
Pure-Vu System: The Pure-Vu System is FDA cleared device intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>did not meet eligibility</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Colonoscopy With Pure-Vu System</title>
          <description>Inpatient colonoscopies with Pure-Vu System- Single Arm&#xD;
Pure-Vu System: The Pure-Vu System is FDA cleared device intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.44" lower_limit="28" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Rate of Adequate Cleansing Level Before and After the Use of the Pure-Vu System</title>
        <description>The rate of adequate cleansing level in each colon segment before and after use of Pure-Vu will be evaluated using the Boston Bowel Preparation Scale (BBPS). Segment score of 0-3 given to each of the 3 segments of the colon (Left side, Transverse and right side) summed for the maximum score of 9 (0= dirtiest and 9= pristine).&#xD;
An adequate cleansing procedure will be considered when all the colon segments will be graded as 2 or above.</description>
        <time_frame>up to 2 hours</time_frame>
        <population>Rate of Adequacy of bowel preparation using the Boston Bowel Preparation Score (BBPS)</population>
        <group_list>
          <group group_id="O1">
            <title>Colonoscopy With Pure-Vu System</title>
            <description>Inpatient colonoscopy procedure with Pure-Vu System&#xD;
Pure-Vu System: The Pure-Vu System is FDA cleared device and CE marking received in February 2018, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.</description>
          </group>
        </group_list>
        <measure>
          <title>The Rate of Adequate Cleansing Level Before and After the Use of the Pure-Vu System</title>
          <description>The rate of adequate cleansing level in each colon segment before and after use of Pure-Vu will be evaluated using the Boston Bowel Preparation Scale (BBPS). Segment score of 0-3 given to each of the 3 segments of the colon (Left side, Transverse and right side) summed for the maximum score of 9 (0= dirtiest and 9= pristine).&#xD;
An adequate cleansing procedure will be considered when all the colon segments will be graded as 2 or above.</description>
          <population>Rate of Adequacy of bowel preparation using the Boston Bowel Preparation Score (BBPS)</population>
          <units>Percentage of Adequate cleansing</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rate of adequate preparation measured by BBPS before Pure-Vu Use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="28" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rate of adequate preparation measured by BBPS after Pure-Vu Use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="90" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From procedure to 48 hours post procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Colonoscopy With Pure-Vu System</title>
          <description>Inpatient colonoscopy procedure with Pure-Vu System&#xD;
Pure-Vu System: The Pure-Vu System is FDA cleared device and CE marking received in February 2018, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Perforation</sub_title>
                <description>After procedure patient reported abdominal pain. Exploratory laparoscopy was performed and an 1 cm tear was repaired with suturing. Patient tolerated the procedure well and discharged 2 days post op. Event was related to retroflexion.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <description>Severity was Mild and resolved in 1 day.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <description>Severity was Mild and resolved in 1 day.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Drop in Hemoglobin</sub_title>
                <description>Severity was Mild and resolved in 2 day.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Operations</name_or_title>
      <organization>Motus GI</organization>
      <phone>954-541-8000</phone>
      <email>anniec@motusgi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

